Kirsch Andrew J, Perez-Brayfield Marcos, Smith Edwin A, Scherz Hal C
Department of Pediatric Urology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA.
J Urol. 2004 Jun;171(6 Pt 1):2413-6. doi: 10.1097/01.ju.0000127754.79866.7f.
With the advent of tissue bulking agents, in particular dextranomer/hyaluronic acid copolymer (Dx/HA), for endoscopic implantation for vesicoureteral reflux (VUR), there has been a major shift in the surgical paradigm throughout Europe, and more recently, in the United States. We describe a modification of the technique used for implantation that has significantly improved our results.
Between October 2001 and October 2003, 285 children 7 months to 15 years old (mean age 4.6 years) underwent endoscopic implantation of Dx/HA for VUR at our institutions. A modified STING (subureteral transurethral injection) procedure (implantation submucosally within the intramural ureter) was introduced during the last year of the study. The average volume of injected material was measured for each ureter. Renal sonography was performed to determine if hydronephrosis was present. At 3 months flouroscopic voiding cystourethrograms were used to evaluate for the presence of VUR. A subset of 122 patients treated with STING (52) were compared to those treated with modified STING (70).
A total of 459 ureters in 231 girls and 54 boys were treated (174 bilateral cases). Mean maximum grade per patient was 2.5/5. Mean injected volume was 0.9 cc ureter. There were 181 patients with at least 3 months of followup. After 1 treatment 76% (137 of 181) of cases were cured (grade 0 reflux), while 54% (24 of 44) of the failures were improved. The overall cure rate was 94% for grade I, 85% for grade II, 78% for grade III and 71% for grade IV reflux. The patients treated with STING had a mean age of 4.8 years, mean maximum reflux grade was 2.5 and success rate was 71% (37 of 52; 86% grade I, 89% grade II, 70% grade III and 63% grade IV reflux). The patients treated with a modified STING had a mean age of 5.5 years, mean maximum grade was 2.8 and a success rate was 89% (62 of 70; 100% grade I, 92% grade II, 91% grade III and 90% grade IV reflux). Ureteral success rates were significantly (p <0.01) greater for the modified STING (92%) vs the standard STING (79%). There were no cases of hydronephrosis at 3 months postoperatively.
The majority of patients undergoing minimally invasive therapy for VUR with Dx/HA are cured after 1 treatment. The modified STING is our preferred method of implant injection for the correction of VUR and in our hands produces a resolution rate of 89% (92% of ureters). The technique optimizes ureteral coaptation, is easy to perform and is not associated with any significant short-term complications. Persistence of VUR in a minority of patients continues to be the only significant adverse effect of endoscopic implantation.
随着组织填充剂,特别是葡聚糖/透明质酸共聚物(Dx/HA)用于内镜下植入治疗膀胱输尿管反流(VUR),整个欧洲以及最近在美国,手术模式发生了重大转变。我们描述了一种对植入技术的改良,该改良显著改善了我们的治疗效果。
2001年10月至2003年10月期间,我们机构对285名年龄在7个月至15岁(平均年龄4.6岁)的儿童进行了内镜下植入Dx/HA治疗VUR。在研究的最后一年引入了改良的STING(输尿管下经尿道注射)手术(在壁内输尿管黏膜下植入)。测量每个输尿管注射材料的平均体积。进行肾脏超声检查以确定是否存在肾积水。在3个月时,使用荧光排尿膀胱尿道造影评估是否存在VUR。将122例接受STING治疗的患者(52例)与接受改良STING治疗的患者(70例)进行了比较。
共治疗了231名女孩和54名男孩的459条输尿管(174例双侧病例)。每位患者的平均最大反流分级为2.5/5。每条输尿管的平均注射体积为0.9 cc。有181例患者至少随访了3个月。1次治疗后,76%(181例中的137例)的病例治愈(0级反流),而54%(44例中的24例)治疗失败的病例病情有所改善。I级反流的总体治愈率为94%,II级为85%,III级为78%,IV级为71%。接受STING治疗的患者平均年龄为4.8岁,平均最大反流分级为2.5,成功率为71%(52例中的37例;I级为86%,II级为89%,III级为70%,IV级为63%)。接受改良STING治疗的患者平均年龄为5.5岁,平均最大分级为2.8,成功率为89%(70例中的62例;I级为100%,II级为92%,III级为91%,IV级为90%)。改良STING的输尿管成功率(92%)显著高于标准STING(79%)(p<0.01)。术后3个月无肾积水病例。
大多数接受Dx/HA微创治疗VUR的患者1次治疗后即可治愈。改良的STING是我们矫正VUR植入注射的首选方法,在我们手中其治愈率为89%(输尿管治愈率为92%)。该技术优化了输尿管贴合,操作简便,且不伴有任何严重的短期并发症。少数患者VUR持续存在仍然是内镜植入的唯一显著不良反应。